Nymox Pharmaceutical Announces Current Safety Monitoring Committee Results and Update for Phase 3 NX-1207 Trials

HASBROUCK HEIGHTS, N.J., Feb. 15, 2012 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) provided an update today on the Company's Phase 3 U.S. trials for NX-1207, Nymox's investigational drug for benign prostatic hyperplasia (BPH). The Safety Monitoring Committee meeting of February 14, 2012 was favorable and indicated no significant safety concerns for the three ongoing U.S. Phase 3 trials to date. Patient recruitment and trial activities for U.S. Phase 3 studies NX02-0017, NX02-0018 and NX02-0020 are ongoing at over 80 well-known urology investigative sites throughout the U.S. Overall accrual numbers for Trials NX02-0017, NX02-0018 and NX02-0020 have reached approximately 980 patients, and good progress is being made toward full enrollment for the pivotal studies.

Back to news